Skip to main content
SpringerLink
Log in

Principles of Drug Metabolism, with an Emphasis on Psychiatric Drugs

  • Protocol
Cell Neurobiology Techniques

Part of the book series: Neuromethods ((NM,volume 33))

  • 727 Accesses

Abstract

A knowledge of how drugs are metabolized in the body is often of clinical relevance because often an administered drug is not soley responsible for observed pharmacological and toxicological effects. Regrettably, the formation of drug metabolites is often not considered in pharmacological evaluations, the assumption being that it is the drug itself that is the active species. In many instances, desirable and undesirable drug effects can be correlated with rates of biotransformations and the properties of metabolites; pharmacokinetic drug-drug interactions may also occur if a patient is receiving two or more drugs that compete for the same metabolic enzymes. In the present chapter, we will concentrate on metabolism of drugs used to treat psychiatric disorders, although the principles and protocols discussed are applicable to other classes of drugs as well.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agúndez, J A., Jiménéz-Jimenez, F. J, Luengo, A., Bernal, M L, Molina, J A., Ayuso, L, Vazquez, A, Parra, J, Duarte, J., Cona, F, Ladero, J M, Alvarez, J. C. and Benitez, J (1995b) Association between the oxidative polymorphism and early onset of Parkinson’s disease. Chn. Pharmacol Ther. 57, 291–269.

    Google Scholar 

  • Agundez, J A, Ledesma, M. C, Ladero, J M., and Benitez, J. (1995a) Preva lence of CYP2D6 gene duplication and its repercussion on the oxidative phe notype in a white population Clin Pharmacol Ther 57, 265–269

    PubMed  CAS  Google Scholar 

  • Ameer, B and Weintraub, R A (1997) Drug interactions with grapefruit juice Clin Pharmacokinet 33, 103–121

    PubMed  CAS  Google Scholar 

  • Arana, G W, Goff, D C, Friedman, H., Ornsteen, M., Greenblatt, D J, Black, B and Shader R.I (1985) Does carbamazepme-induced reduction of plasma ha loperidol levels worsen psychotic symptoms? Am J Psychiatry 143, 650–651

    Google Scholar 

  • Anens’ E. J., Wuis, E. W., and Vennga, E. J. (1988) Stereoselectivity of bioactive xenobiotics Biochem Pharmacol 37, 13–18.

    Google Scholar 

  • Baker, G B, Coutts, R T, and Holt, A. (1994) Metabolism and chirality in psy chopharmacology Biol Psychiatry 36, 211–213

    PubMed  CAS  Google Scholar 

  • Baker, G B, Urichuk, L J, and Coutts, R T (1998) Drug metabolism and meta bolic drug-drug interactions in psychiatry. Child and Adolescent Psycho pharmacol News (suppl)., in press.

    Google Scholar 

  • Balant-Gorgm, E. A and Balant, L P (l995)Therapeutic drug monitoring relevance during the drug treatment of psychiatric disorders CNS Drugs 4, 243–253

    Google Scholar 

  • Baldessarini, P A and Cole J O (1995) Interactions of serotonin reuptake inhibi tors with tricyclic antidepressants-in reply. Arch Gen Psychiat 52, 784,785

    Google Scholar 

  • Baumann, P (1996a) Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors Clin Pharmacokinet 31, 444–469

    PubMed  CAS  Google Scholar 

  • Baumann, P (1992) Clinical pharmacokinetics of citalopram and other selective serotonin reuptake inhibitors (SSRI) Int Clin Psychopharmacol 6, 13–20

    PubMed  Google Scholar 

  • Baumann, P. (1996b) Pharmacology and pharmacokinetics of citalopram and other SSRls Int Clin Psychopharmacol ll(Suppl.), 5–11

    Google Scholar 

  • Baumann, P and Rochat, B (1995) Comparative pharmacokinetics of selective serotonin reuptake inhibitors a look behind the mirror Int Clin Psycho pharmacol 10(Suppl.), 15–21

    Google Scholar 

  • Benet, L Z, Kroetz, D L., and Sheiner, L B (1996) Pharmacokinetics the dynamics of drug absorption, distribution and elimination, in Goodman & Gilman’s The Pharmacological Basis of Therapeutics (Hardman, J G, Limbird, L E, Molinoff, P. B and Ruddon, R W, eds), McGraw-Hill, New York

    Google Scholar 

  • Bergstrom, R F, Peyton, A L, and Lemberger, L (1992) Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction Clin Pharmacol Ther 51, 239–248

    PubMed  CAS  Google Scholar 

  • Bertilsson, L, Carrillo, J A, Dahl, M L, Llerena, A, Aim, C, Bondesson, U, Lindstrom, L, Rodriguez de la Rubia, I, Ramos, S, and Benitez, J (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caf feine test Br J Clin Pharmacol 38, 471–473

    PubMed  CAS  Google Scholar 

  • Bertilsson, L, Henthorn, T K, Sanz, E, Tybring, G, Sawe, J, and Villen, T (1989) Importance of genetic factors in the regulation of diazepam meta bolism Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype Clin Pharmacol Ther 45, 348–355

    PubMed  CAS  Google Scholar 

  • Bertz, R J and Granneman, G R. (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions Clin Pharmacokinet 32, 210–258

    PubMed  CAS  Google Scholar 

  • Blake, B L, Rose, R. L, Mailman, R. B, Levi, P. E, and Hodgson, E (1995) Metabolism of thioridazine by microsomal monooxygenases relative roles of P450 and flavin-containing monooxygenase. Xenobiotica 25, 377–393

    PubMed  CAS  Google Scholar 

  • Bolaji, O O, Coutts, R T, and Baker, G B (1993) Metabolism of tnmipramine in vitro by human CYP2D6 isozyme Res Commun Chem Path Pharmacol 82, 111–120

    CAS  Google Scholar 

  • Boulton, A A, Baker, G B., and Coutts, R T., eds (1988) Analysis of psychiat ric drugs Neuromethods, vol. 10, Humana Press, Totowa, New Jersey

    Google Scholar 

  • Bourne, M, Meunier, V, Berger, Y, and Fabre, G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions cata lyzed by human liver microsomes. J Pharmacol Exp Ther 277, 321–332

    Google Scholar 

  • Brenner, D D and Schellens, J H M. (1990) A’ cocktail’ strategy to assess in vivo oxidative drug metabolism in humans Trends Pharmacol Sci 11, 223–225

    Google Scholar 

  • Britto, M R and Wedlund, P J (1992) Cytochrome P-450 in the brain Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes Drug Metab Dispos 20, 446–450

    PubMed  CAS  Google Scholar 

  • Brosen, K (1993a) Isozyme specific drug oxidation: genetic polymorphism and drug-drug interactions. Nord J Psychiat. 47(Suppl. 30), 21–26.

    Google Scholar 

  • Brosen, K (1993b) The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest. 71, 1002–1009

    CAS  Google Scholar 

  • Brosen, K and Skjelbo, E (1991) Fluoxetine and norfluoxetine are potent inhibitors of P450IID6-the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 32, 137,138

    Google Scholar 

  • Caldwell, J (1992) The importance of stereochemistry in drug action and disposition J Clin Pharmacol. 32, 925–929

    PubMed  CAS  Google Scholar 

  • Caldwell, J (1996) Importance of stereospecific bioanalytical monitoring in drug development J Chromatogr 719, 3–13

    CAS  Google Scholar 

  • Camilleri, P, de Baisi, V,, and Hutt, A (1994) Resolving the problem Chemistry in Britain, 30, 43–46

    CAS  Google Scholar 

  • Carson, S. W (1996) Pharmacokinetic and pharmacodynamic drug interactions with polypharmacotherapy of treatment-resistant affective and obsessive compulsive disorders. Psychopharmacol. Bull 32, 555–568

    CAS  Google Scholar 

  • Cholerton, S., Daley, A K, and Idle, J R (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response Trends Pharmacol Sci 13, 434–439

    PubMed  CAS  Google Scholar 

  • Ciraulo, D A, Shader, R 1, Greenblatt, D J., and Creelman, W. L, eds (1995) Drug Interactions in Psychiatry, Williams & Wilkins, Baltimore, MD

    Google Scholar 

  • Ciraulo, D. A. and Shader R. 1 (1990a) Fluoxetine drug-drug interactions I Antidepressants and antipsychotics J Clin Psychopharmacol 10, 48–50

    PubMed  CAS  Google Scholar 

  • Ciraulo, D A, and Shader R. 1. (1990b) Fluoxetine drug-drug interactions II J Clin. Psychopharmacol. 10, 213–217

    PubMed  CAS  Google Scholar 

  • Coutts, R. T (1994) Polymorphism in the metabolism of drugs, including antidepressant drugs comments on phenotyping J Psychiat Neurosci 19, 30–44

    CAS  Google Scholar 

  • Coutts, R T., Bach, M. V., and Baker, G B (1997) Metabolism of amitriptyline with CYP2D6 expressed in a human cell line Xenobiotica 27, 33–47

    PubMed  CAS  Google Scholar 

  • Coutts, R T, Su, P., Baker, G B, and Daneshtalab, M (1993) Metabolism of lmipramine in vitro by CYP2D6 expressed in a human cell line, and observa tions on metabolite stability J Chromatogr Biomed Appl 6115, 265–272

    Google Scholar 

  • Coutts, R T and Baker, G B (1989) Implications of chirahty and geometric isomerism in some psychoactive drugs and their metabolites Chirahty 99–120

    Google Scholar 

  • Daniel, W (1995) Metabolism of psychotropic drugs’ pharmacological and clini cal relevance Pol J Pharmacol Pharm 47, 367–379

    CAS  Google Scholar 

  • Degtyarenko, K N and Fabian, P (1996) The directory of P450-contaming sys tems on WorldWide Web Computer Appl. Bwsctences 12, 237–240.

    CAS  Google Scholar 

  • DeVane, C L (1994) Pharmacogenetics and drug metabolism of newer anti depressant agents J Clin Psychiat 55(Suppl.), 38–45

    Google Scholar 

  • Drayer, D E (1988) Problems in therapeutic drug monitoring the dilemma of enantiomeric drugs in man Ther Drug Monit 10, 1–7

    PubMed  CAS  Google Scholar 

  • Ducharme, J, Fernandez, C, Gimenez, F., and Fannotti, R. (1996) Critical issues in chiral drug analysis in biological fluids by high-performance liquid chro matography J Chromatog B Biomed Appl 686, 65–75

    CAS  Google Scholar 

  • Eap, C. B, Bertschy, G, Powell, K, and Bauman, P (1997) Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enan tiomers of methadone J. Clin Psychopharmacol 17, 113–117

    PubMed  CAS  Google Scholar 

  • Eap, C B and Baumann, P (1996) Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients J. Chromatogr 686, 51–63

    CAS  Google Scholar 

  • Edge, S C, Markowitz, J S, and DeVane, L. (1997) Clozapine drug-drug inter actions. a review of the literature Human Psychopharmacol 12, 5–20

    CAS  Google Scholar 

  • Eichelbaum, M (1992) Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Bwchem Pharmacol 37, 93–96

    Google Scholar 

  • Eiermann, B M, Engel, G., Johansson, I, Zanger, U M, and Bertilsson, L (1997) The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine Br J Clin. Pharmacol 44, 439–446.

    PubMed  CAS  Google Scholar 

  • Ereshefsky, L., Riesenman, C, and Lam, Y M F (1995) Antidepressant drug interactions and the cytochrome P450 system the role of cytocyrome P450 2D6 Clin Pharmacokinet 29, 10–19

    PubMed  CAS  Google Scholar 

  • Fang, J, Coutts, R T, McKenna, K F, and Baker, G B (1998) Elucidation of individual cytochrome P450 enzymes involved m the metabolism of clozapine Naunyn Schmiedeberg’s Arch Pharmacol (in press).

    Google Scholar 

  • Fang, J, Baker, G B., Silverstone, P H, and Coutts, R T (1997) Involvement of CYP3A4 and CYP2D6 in the metabolism of halopendol Cell Mol Neurobiol 17, 227–233.

    PubMed  CAS  Google Scholar 

  • Fang J, Baker G. B, Coutts R T., and McKenna K F (1996) Elucidation of indi vidual cytochrome P450 isoenzymes involved in the metabolism of clozapine Proc 7th North American ISSX Meeting, San Diego, California, USA, October 20-24, 1996.

    Google Scholar 

  • Gaedigk, A, Blum, M, Gaedigk, R., Eichelbaum, M, and Meyer, U A. (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabohzers of the debrisoqume/sparteine poly morphism Am J Hum Genet 48, 943–950

    PubMed  CAS  Google Scholar 

  • Garfinkel, D (1958) Studies on pig liver microsomes 1 Enzymatic and pig ment composition of different microsomal fractions Arch Biochem Bio physics 77, 493–509

    CAS  Google Scholar 

  • Gibaldi, M (1993) Stereoselective and isozyme-selective drug interactions Chirality 5, 407–413

    PubMed  CAS  Google Scholar 

  • Gibson, G G and Skett, P (1988) Introduction to Drug Metabolism, Chapman and Hall, London

    Google Scholar 

  • Glue, P. and Clement, R P (1998) Cytochrome P-450 enzymes and drug metabolism-basic concepts and methods of assessment Cell Mol Neurobwl (in press)

    Google Scholar 

  • Glue, P and Banfield, C (1996) Psychiatry, psychopharmacology and P-450s Hum Psychopharmacol. 11, 97–114

    CAS  Google Scholar 

  • Goldstein, J. A, Faletto, M. B., Romkes-Sparks, M., Sullivan, T, Kitareewan, S, Raucy, J L, Laskar, J. M and Ghanayem, B. 1 (1994) Evidence that CYP2C19 is the major (S)mephenytoin 4’-hydroxylase in humans Biochemistry 33, 1743–1752

    PubMed  CAS  Google Scholar 

  • Gonzales, F J. and Korzedwa, K R (1995) Cytochrome P450 expression systems Ann Rev Pharmacol Toxicol 35, 369–390

    Google Scholar 

  • Gorog, S and Gazdag, M. (1994) Enantiomeric derivatization for biomedical chromatography J Chromatogr 659, 51–84

    CAS  Google Scholar 

  • Greenblatt, D J., von Moltke, L L, Schmider, J., Harmatz, J S, and Shader, R. I. (1996) Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine in vitro and in vivo studies J Clin Pharmacol 36, 792–798.

    PubMed  CAS  Google Scholar 

  • Guengerich, F. P (1995) Human cytochrome P-450 enzymes, in Cytochrome P-450, 2nd Ed. (Ortiz de Montellano, P. R, ed.), Plenum Press, New York

    Google Scholar 

  • Hamehn, B A., Turgeon, J., Vallee, F., Belanger, P M., Paquet, F, and LeBel, M. (1996) The disposition of fluoxetine but not sertraline is altered in poor metabohzers of debrisoquin. Clin Pharmacol. Ther 60, 512–521

    Google Scholar 

  • Hansson, T, Tindberg, N, Ingelman-Sundberg, M, and Kohler, C (1990) Regional distribution of ethanol-inducible cytochrome P450 IIEl in the rat CNS. Neuroscience 34, 451–463

    PubMed  CAS  Google Scholar 

  • Harvey, A. T and Preskorn, S. H. (1996a) Cytochrome P450 enzymes interpre tation of their interactions with selective seroltonin reuptake inhibitors Part I J Clin. Psychopharmacol 16, 273–285.

    PubMed  CAS  Google Scholar 

  • Harvey, A. T and Preskorn, S H. (1995) Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch. Gen Psvchtat 52, 783,784

    Google Scholar 

  • Harvey, A. T. and Preskorn, S. H. (1996b) Cytochrome P450 enzymes interpre tation of their interactions with selective seroltonin reuptake inhibitors, Part II. J Clin Psychopharmacol 16, 345–354

    PubMed  CAS  Google Scholar 

  • Hedlund, E, Wyss, A, Kainu, T, Backlund, M, Kohler, C, Pelto-huikko, M., Gustafsson, J-A and Warner, M (1996) Cytochrome P4502D4 in the brain specific neuronal regulation by clozapine and toluene. Mol Pharmacol 50, 342–350.

    PubMed  CAS  Google Scholar 

  • Heim, M. H. and Meyer, U. A (1991) Genetic polymorphism of debrisoquine oxidation4 restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6 Meth Enzymol 206, 173–183

    PubMed  CAS  Google Scholar 

  • Henthorn, T. K., Benitez, J, Avram, M. J., Martinez, C, Lierena, A, Cobaleda, J., Krejcie, T C, and Gibbons, R. D (1989) Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin Pharmacol Ther 45, 328–333.

    PubMed  CAS  Google Scholar 

  • Houston, J B. (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol, 47, 1469–1479

    PubMed  CAS  Google Scholar 

  • Huang, M-L., Van Peer, A., Woestenborghs, R, DeCoster, R, Heykants, J, Jansen, A. A. I, Zylicz, Z Visscher, H W, and Jonkman, J H G (1996) Pharmacokinetics of the novel antipsychotic agent risperidone and the pro lactin response in healthy subjects Clin Pharmacol Ther 54, 257–268.

    Google Scholar 

  • Hubbard, J. W., Ganes, D, Lim, H. K., and Midha, K K (1986) Chiral pharmacol ogy and its consequences for therapeutic monitoring Clin Btochem 19, 107–112.

    CAS  Google Scholar 

  • Hutt, A. J and Tan, S C (1996) Drug chirality and its clinical significance Drugs 52, 1–12

    PubMed  CAS  Google Scholar 

  • Hutt, A. J, Hadley, M. R., and Tan, S. C (1994) Enantiospecific analysis Applica tions in bioanalysis and metabolism. Eur J Drug, Metab Pharmacokin 19, 241–251.

    CAS  Google Scholar 

  • Jamah, F, Mahvar, R., and Pasutto, F, M (1989) Enantioselective aspects of drug action and disposition, therapeutic pitfalls. J Pharm Sci 78, 695–715

    Google Scholar 

  • Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S, Poulsen, H E, and Brosen, K, (1996) Dose-dependent inhibition of CYP1A2, CYP2C19, CYP2D6 by citalopram, fluoxetine, fluvoxamine, and paroxetine Eur J Clin Pharmacol 51, 73–78

    PubMed  CAS  Google Scholar 

  • Jerling, M, Dahl, M-L, Aberg-Wistedt, A, et al (1996) The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol Chn Pharmacol Ther 59, 423–428

    CAS  Google Scholar 

  • Kalow, W. and Tyndale, R. F. (1992) Debrisoquine/sparteine monooxygenase and other P-450s in the brain, in Pharmacogenetics of Drug Metabolism. International Encyclopedia of Pharmacology and Therapeutics (Kalow, W, ed), Pergamon Press, New York, pp 649–656

    Google Scholar 

  • Kempermann, G, Knoth, R., Gebicke-Haerter, P J, Stolz, B J, and Yolk, B (1994) Cytochrome P450 in rat astrocytes in vivo and in vitro intracellular localization and induction by phenytoin J. Neurosci Res 39, 576–588

    PubMed  CAS  Google Scholar 

  • Kobayashi, K, Yamamoto, T., Chiba, K., Tani, M, Ishizak, T, and Kurolwa, Y (1995)The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4’-hydroxylase activity in human liver microsomes Br J Clin Pharmacol 40, 481–485

    PubMed  CAS  Google Scholar 

  • Kroemer, H K and Eichelbaum, M (1995) It’s the genes, stupid Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymor phism. Life Sci 56, 2285–2298

    PubMed  CAS  Google Scholar 

  • Kronbach, T, Mathys, D, Umeno, M, Gonzalez, F J, and Meyer, U A (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4 Mol Pharmacol 36, 89–96

    PubMed  CAS  Google Scholar 

  • Kopfer, A and Preisig, R (1984) Pharmacogenetics of mephenytoin a new drug hydroxylation polymorphism in man Eur J Clm Pharmacol 26, 753–759

    Google Scholar 

  • Lam, Y W F, Jann, M W, Chang, W-H, Yu, H-S, Lin, S-K., Chen, H., and Davis, C. M. (1995) Intra-and interethnic variability m reduced halopendol to halopendol ratios J Clin Pharmacol 35, 128–136

    PubMed  CAS  Google Scholar 

  • Lane, R M. (1996) Pharmacokinetic drug interaction potential of selective sero tonin reuptake inhibitors. Int Clin Psychopharmacol 11, 31–61

    PubMed  Google Scholar 

  • Lane, R M and Baker, G B (1998) Chirality and drugs used in psychiatry nice to know, or need to know? Cell Mol Neurobiol (in press)

    Google Scholar 

  • Liccione, J J and Maines, M D (1989) Manganese-mediated increase in the rat brain mitochondrial cytochrome-P-450 and drug metabolism activity-sus ceptibility of the striatum J Pharmacol Exp Ther 248, 222–228

    PubMed  CAS  Google Scholar 

  • Lin, K.-M, Poland, R E, Wan, Y-J Y, Smith, W, and Lesser, I M (1996) The evolving of pharmacogenetics clinical and ethnic perspectives Psychopharmacol Bull 32, 205–217

    PubMed  CAS  Google Scholar 

  • Marzo, A (1994) Incoming guidelines on chirality-A challenge for pharmaco kinetics in drug development Arzneimittelforschung 44-1, 6

    Google Scholar 

  • Messiha, F S (1993) Fluoxetine, adverse effects and drug-drug interactions Clin Toxicol 31, 603–630

    CAS  Google Scholar 

  • Meyer, U A, Amnen, R, Balant, L P, Bertilsson, L, Eichelbaum, M, Geuntert, T. W, Henauer, S, Jackson, P, Laux, G, Mikkelson, H, Peck, C, Pollock, B G, Proest, R, Sjoqvist, F, and Denhni-Stula, A (1996) Antidepressants and drug-metabolizing enzymes-expert group report Acta Psychiat Scand 93, 71–79

    PubMed  CAS  Google Scholar 

  • Midha, K K, Hawes, E M, Hubbard, J W, Korchinski, E D, and McKay G (1987) The search for correlations between neuroleptic plasma levels and clinical outcome a critical review, in Psychopharmacology The Third Genera tion of Progress (Meltzer, H Y, ed), Raven Press, New York

    Google Scholar 

  • Miners, J O and Birkett, D J (1998) Cytochrome P4502C9-an enzyme of major importance in human drug metabolism Br J Clin Pharmacol 45, 525–538

    PubMed  CAS  Google Scholar 

  • Muralidharan, G, Hawes, E M, McKay, G, Korchmski, E D, and Midha, K K (1991) Qumidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase Eur J Pharmacol 41, 471–474

    CAS  Google Scholar 

  • Mutschler, E, Gietl, Y, Krauss, D, Martin, E., Pflugmann, G, and Weber, H (1990) Stereospecif ic analysis and human pharmacokinetics of the enantiomers of drugs administered as racemates, in Chirality and Biological Activity (Holmstedt, B, Frank, H, and Testa, B, eds), Alan R Liss, New York, pp.199–219

    Google Scholar 

  • Nebert, D W, Nelson, D R, Adesnik, M, Coon M J, Estabrook, R W, Gonzalez, F J, Guengerich, F P, Gunsalus, I C, Johnson, E. F, Kemper, B, Levin, W, Philips, I R, Sato, R and Waterman, M R (1989) The P450 super-family. updated listing of all genes and recommended nomenclature for the chromosomal loci DNA 8, 1–13

    PubMed  CAS  Google Scholar 

  • Nelson, D R, Kamataki, T, Waxman, D. J, Guengerich, F L, Estabrook, R W, Feyereisen, R, Gonzalez, F J, Coon, M J, Gunsalus, I C, Gotoh, O, Okuda, K, and Nebert, D W (1993) The P450 superfamily update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature DNA Cell Biol 12, 1–51

    PubMed  CAS  Google Scholar 

  • Nelson, D R, Koymans, L, Kamataki, T., Stegeman, J J, Feyereisen, R, Waxman, D J, Waterman, M R, Gotoh, O, Coon, M J, Estabrook, R W, Gunsalus, I C, and Nebert, D W (1996) P450 superfamily update on new sequences, gene mapping, accession numbers and nomenclature Pharmacogenetics 6, 1–42.

    PubMed  CAS  Google Scholar 

  • Nemeroff, C B, DeVane, C L, and Pollock, B G (1996) Newer antidepres sants and the cytochrome P450 system Am J Psychiat 153, 311–320

    PubMed  CAS  Google Scholar 

  • Olkkola, K T, Aranko, K, Luunla, H, Hiller, A, Saaemvaara, L, Himberg, J J, and Neuvonen, P J (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53, 298–305

    PubMed  CAS  Google Scholar 

  • Omura, T and Sato, R (1962) A new cytochrome in liver microsomes J Biol Chem 237, PC1375–PC1376

    Google Scholar 

  • Ortiz de Montellano, P R, ed (1996) Cytochrome P450, in, Structure, Mecha nism, and Biochemistry, 2nd ed, Plenum Press, New York

    Google Scholar 

  • Parkinson, A (1996) Biotransformation of xenobiotics, in Casarett and Doull’s Toxicology The Basic Science of Poisons, 5th edition (Klaasen, C D, ed), McGraw-Hill, New York, NY, pp 113–186.

    Google Scholar 

  • Perault, M C, Bouquet, S, Bertschy, G, Vandel, S, Chakroun, R, Guibert, S, and Vandel, B (1991) Debnsoqume and dextromethorphan phenotyping and antidepressant treatment. Therapie 46, 1–3.

    PubMed  CAS  Google Scholar 

  • Pirmohamed, M, Williams, D., Madden, S, Templeton, E, and Park, B K (1995) Metabolism and bioactivation of clozapine by human live in vitro J Pharmacol Exp Ther 272, 984–990

    PubMed  CAS  Google Scholar 

  • Poph, A, Baldessarim, R. J, and Cole, J O. (1995) Interactions of serotonin reuptake inhibitors with tricyclic antidepressants-in reply. Arch Gen Psy chiatry, 52, 784,785

    Google Scholar 

  • Potter, W Z and Manji, H K. (1990) Antidepressants, metabolites, and appar ent drug resistance Clin Neuropharmacol 13(Suppl. 1), S45–S53

    PubMed  Google Scholar 

  • Preskorn, S H (1996) Clinical Pharmacology of Selective Serotonin Reuptke Inhibi tors, 1st ed, Professional Communications Inc, Caddo, OK

    Google Scholar 

  • Preskorn, S H (1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors an overview with emphasis on pharmacokinetics and ef fects on oxidative drug metabolism Clin Pharmacokinet 32,(Suppl. 1), 1–21

    PubMed  CAS  Google Scholar 

  • Raitasuo, V, Lehtovaara, R, and Huttunen, M O (1993) Carbamazepine and plasma levels of clozapine. Am J Psychiatry 150, 169

    PubMed  CAS  Google Scholar 

  • Richelson, E (1997) Pharmacokinetic drug interactions of new antidepressants A review of the effects on the metabolism of other drugs Mayo Clin Proc 72, 835–847.

    PubMed  CAS  Google Scholar 

  • Ring, B J, Catlow, J, Lindsay T, Gillespie, T, Roskos, K, Cenmele, B J, Swanson, S P, Hamman, M. A, and Wrighton, S A (1996) Identification of the human cytochromes P450 responsible for the invitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine J Pharmacol Exp Ther 276, 658–666

    PubMed  CAS  Google Scholar 

  • Rodngues, A D (1994) Use of in vitro human metabolism studies in drug development. Biochem Pharmacol. 48, 2147–2156.

    Google Scholar 

  • Rosholm, N F. and Brosen, K (1995) Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism Eur J Clin Pharmacol 48, 501–504

    PubMed  Google Scholar 

  • Rudorfer, M V and Potter, W Z (1985) Metabolism of drugs used in affective disorders, in Pharmacotherapy of Affective Disorders, Theory and Practice (Dewhurst, W G and Baker, G B, eds.), N Y University Press, New York, pp 382–448

    Google Scholar 

  • Schmid, B, Bircher, J, Preisig, R and Kupfer, A (1989) Polymorphic dextromethorphan metabolism. Cosegregation of oxidative O-demethylation with debnsoquine hydroxylation Clin Pharmacol Ther 38, 618–624

    Google Scholar 

  • Schmider, J., Greenblatt, D J., von Moltke, L L., Karsov, D, and Shader, R I (1997) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro studies of phenytoin p-hydroxylation J Clin Pharmacol 44, 495–498

    CAS  Google Scholar 

  • Schung, V (1994) Enantiomer separation by gas chromatography on chiral sta tionary phases J Chromatog 666, 111–129

    Google Scholar 

  • Segel, I H (1975) Enzyme Kinetics Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, John Wiley and Sons, New York, NY

    Google Scholar 

  • Sequeira, D J and Strobel, H W. (1996) In vitro metabolism of imipramine by brain micosomes effects of inhibitors and exogenous cytochrome P450 reductase. Brain Res 738, 24–31.

    PubMed  CAS  Google Scholar 

  • Shen, W. W (1997) The metabolism of psychoactive drugs A review of enzy matic biotransformation and inhibition Biol Psychiatry 41, 814–826

    PubMed  CAS  Google Scholar 

  • Shimada, T, Yamazaki, H., Mimura, M, Inui, Y, and Guengench, F P (1994) Intenndividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals Studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exper Ther 270, 414–423

    CAS  Google Scholar 

  • Smith, D. F (1984) CRC Handbook of Stereoisomers Drugs in Psychopharmacology, CRC Press Inc., Boca Raton, FL

    Google Scholar 

  • Spina, A, Avenoso, A, Campo, G, Caputi, A. P, and Perucca, E (1995) The ef fect of carbamazepine on the 2-hydroxylation of desipramine Psychopharmacol 117, 413–416.

    CAS  Google Scholar 

  • Spina, E and Perucca, E (1994) New and older antidepressants a comparative review of drug interactions CNS Drugs 2, 479–497

    Google Scholar 

  • Sproule, B. A, Naranjo, C A., Bremmer, K. E, and Hassan, P C (1997) Selec tive serotonin reuptake inhibitors and CNS drug interactions Clin Pharmacokinet 33, 454–471

    PubMed  CAS  Google Scholar 

  • Srinivas, N R, Shyu, W C, and Barbhalya, R, H (1995) Gas chromatographic determination of enantiomers as diastereomers following pre-column derivatization and applications to pharmacokinetic studies, a review Biomed Chromatog 9, 1–9

    CAS  Google Scholar 

  • Su, P., Coutts, R T, Baker, G. B., and Daneshtalab, M. (1993) Analysis of uni pramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line Xenobiotica 23, 1289–1298

    PubMed  CAS  Google Scholar 

  • Subert, J (1994) Progress in the separation of enantiomers of chiral drugs by HPLC without their prior derivatization. Pharmazie 49, 3–13.

    CAS  Google Scholar 

  • Syrek, M., Wojcikowski, J, and Daniel, W. (1996) Effect of carbamazepine on the pharmacokinetics of promazine. Pol.J Pharmacol 48, 601–608

    PubMed  CAS  Google Scholar 

  • Taylor, D. (1995) Selective serotonin reuptake inhibitors and tricyclic antide pressants in combination Interactions and therapeutic uses. Br J Psychiatry 167, 575–580

    PubMed  CAS  Google Scholar 

  • Taylor, D. and Lader, M (1996) Cytochromes and psychotropic drug interactions Br. J Psychiat 168, 529–533.

    CAS  Google Scholar 

  • Teboul, E. and Chouinard, G. (1991) A guide to benzodiazepine selection, part II, clinical aspects. Can J Psychiat. 36, 62–73

    CAS  Google Scholar 

  • Terabe, S., Otsuka, K., and Nishi, H (1994) Separation of enantiomers by capil lary electrophoretic techniques J Chromatogr. A. 666, 295–319

    CAS  Google Scholar 

  • Testa, B (1986) Chiral aspects of drug metabolism Trends Pharmacol Set 7, 60–64

    CAS  Google Scholar 

  • Van Harten, J (1993) Clinical pharmacokinetics of selective serotonin reuptake inhibitors Clin Pharmacokinet 24, 203–220

    PubMed  Google Scholar 

  • Vespalec, R and Bocek, P (1994) Chiral state of the art. Electrophoresis 15, 755–762

    PubMed  CAS  Google Scholar 

  • von Bahr, C, Movin G, Nordin, C, Linden, A, Hammarlund-Udenases, M., Hedberg, A, Ring, H., and Sjoquist, F. (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype Clin Pharmacol Ther 49, 234–240.

    Google Scholar 

  • von Moltke, L L, Greenblatt, D J, Harmatz, J. S., and Shader, R. 1 (1993) Alprazolam metabolism m vitro studies of man, monkey, mouse and rat liver microsomes Pharmacology 47, 268–276.

    Google Scholar 

  • von Moltke, L. L., Greenblatt, D J., Harmatz, J. S, Duan, S. X., and Harrel, L. M. (1996) Triazolam biotransformation by human liver microsomes in vitro effects of metabolic inhibitors and clinical confirmation of a predicted inter action with ketoconazole. J Pharmacol Exp Ther 276, 370–379

    Google Scholar 

  • von Moltke, L L, Greenblatt, D. J, Duan, S. X, Schmider, J, Kudchadker, L, Fogelman, S. M, Harmatz, J S., and Shader, R 1. (1996) Phenacetm O-dee thylation by human liver microsomes in vitro, inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology 128, 398–407.

    Google Scholar 

  • von Moltke, L L, Greenblatt, D J, Cotreau-Bibbo, M., Duan, S X., Harmatz, J. S., and Shader, R. 1. (1994) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake inhibitor antidepressants, and by quinine and ketoconazole a model system to predict drug interactions in vivo. J Pharmacol. Exp Ther 268, 1278–1283.

    Google Scholar 

  • Warner, M., Stromstedt, M., Wyss, A., and Gustafsson, J-A. (1993) Regulation of cytochrome P450 in the central nervous system J Steroid Bwchem Mol Biol 47, 191–194

    CAS  Google Scholar 

  • Waterman, M. R., Jenkins, C. M., and Pikuleva, I. (1995) Genetically engineered bacterial cells and applications. Toxicol. Lett 82183, 807–813

    Google Scholar 

  • Witte, D T, Ensing, K, Franke, J P, and Dezeeuw, R A (1993) Development and registration of chiral drugs Pharm World Sei 15, 10–16.

    CAS  Google Scholar 

  • Wrighton, S. A and Stevens, J C (1992) The human hepatic cytochromes P450 involved in drug metabolism Critical Reviews in Toxicology 22, 1–21

    PubMed  CAS  Google Scholar 

  • Wu, D, Otton, S. V, Kalow, W., and Sellers, E. M (1995) Effects of route of administration on dextromethorphan pharmacokinetics and behavioural response in the rat J Pharmacol Exp Ther 274, 1431–1437

    PubMed  CAS  Google Scholar 

  • Yasui, N, Koichi, O, Kaneko, S, et al (1996) A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism Clin Pharmacol Ther 59, 514–519

    PubMed  CAS  Google Scholar 

  • Yasumon, T, Qing-Hua, L, Yamazoe, Y, et al (1994) Lack of low Km diaz epam N-demethylase in livers of poor metabohzers for S-mephenytoin 4-hydroxylation Pharmacogenetics 4, 323–331

    Google Scholar 

  • Young, R C (1991) Hydroxylated metabolites of antidepressants Psychopharmacol Bull 27, 521–532

    PubMed  CAS  Google Scholar 

  • Young, D, Midha, K K, Fossler, M J., Hawes, E M, Hubbard, J W, McKay, G, and Korchinski, E D. (1993) Effect of qumidine on the interconversion kinetics between halopendol and reduced halopendol in humans implica tions for the involvement of cytochrome P450IID6 Eur J Clin Pharmacol 44, 433–438.

    PubMed  CAS  Google Scholar 

  • Zum Brunnen, T L and Jann, M W (1998) Drug interactions with antipsy chotic agents CNS Drugs 9, 381–401

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurochemzcal Research Unit, Department of Psychiatry, Walker Mackenzie Centre, University of Alberta, Edmonton, Alberta, Canada

    Ronald T. Coutts

  2. College of Pharmacy and Nutrition, Universtty of Saskatchewan, Saskatoon, Saskatchewan, Canada

    jian Fang

  3. Laboratozre de Pharmcologie, Faculté de Médecine, Université de Nantes, Nantes, France, and Neurochemical Research Unit, Department of Psychiatry, Walker Mackenzze Centre, University of Alberta, Edmonton, Alberta, Canada

    Michel Bourin

  4. Neurochemical Research Unit, Department of Psychiatry, Walker Mackenzie Centre, University of Alberta, Edmonton, Alberta, Canada

    Glen B. Baker

Authors
  1. Ronald T. Coutts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. jian Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel Bourin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Glen B. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Humana Press Inc

About this protocol

Cite this protocol

Coutts, R.T., Fang, j., Bourin, M., Baker, G.B. (1999). Principles of Drug Metabolism, with an Emphasis on Psychiatric Drugs. In: Cell Neurobiology Techniques. Neuromethods, vol 33. Humana Press. https://doi.org/10.1385/0-89603-510-7:255

Download citation

  • DOI: https://doi.org/10.1385/0-89603-510-7:255

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-510-2

  • Online ISBN: 978-1-59259-638-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation